Rituximab in relapsing or refractory ANCA-associated vasculitis: A case series of 16 patients

Scandinavian Journal of Rheumatology

Volumn 41, Issue 2, 2012, Pages 116-119

  Wendt, M ^a   Gunnarsson, I ^a   Bratt, J ^a   Bruchfeld, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; C REACTIVE PROTEIN; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ANEMIA; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CYTOMEGALOVIRUS RETINITIS; DISEASE ACTIVITY; DRUG FATALITY; DRUG INDICATION; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PYELONEPHRITIS; RELAPSE; REVIEW; SALMONELLOSIS; SCORING SYSTEM; SEPSIS; SIDE EFFECT; SINUSITIS; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; VIRUS REACTIVATION; WEGENER GRANULOMATOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; VASCULITIS; YOUNG ADULT;

EID: 84858420666     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2011.620573     Document Type: Review

References (12)

1. Novak SN, Pearson CM. Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med 1971;284:938-42.
2. Jayne D. Role of rituximab therapy in glomerulonephritis. J Am Soc Nephrol 2010;21:14-17.
3. Lovric S, Erdbryegger U, Kumpers P, Woywodt A, Koenecke C, Wedemeyer H, et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmatic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 2009; 24:179-85.
4. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:2156-68.
5. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994;87:671-8.
6. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
7. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
8. Segelmark M, Phillips BD, Hogan SL, Falk RJ, Jennette JC. Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis. Clin Diagn Lab Immunol 2003;10:769-74.
9. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005;11:189-91.
10. Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004;83:58-60.
11. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20.
12. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010;89:255-62.